CN Stock MarketDetailed Quotes

300110 Huaren Pharmaceutical

Watchlist
  • 3.92
  • -0.09-2.24%
Market Closed Dec 4 15:00 CST
4.63BMarket Cap31.61P/E (TTM)

About Huaren Pharmaceutical Company

The company was founded in May 1998. It is a modern medical and health industry group integrating R&D, production and sales, focusing on preparations, APIs, pharmaceutical packaging materials and medical devices. In August 2010, the company was successfully listed on the Shenzhen Stock Exchange. In July 2019, the company changed its shares, and the Xi'an Qujiang New Area Management Committee became the actual controller of the company. The company is a state-owned pharmaceutical and health industry group integrating R&D, production, and sales, with products such as narcology, respiratory medicine, nephrology, therapeutic high-capacity preparations, medical devices, etc., with basic infusions and health products as the two wings, and comprehensive collaborative development of raw materials, pharmaceuticals, pharmaceutical packaging, medical devices, etc. The company's main products: basic infusion, blood volume booster, blood purification, anti-infective, circulatory system, hemostasis, neurological, anti-hepatitis and hepatitis adjuvant products, peritoneal dialysis solution, low calcium peritoneal dialysis solution, doxophylline injection, compound potassium hydrogen phosphate injection, fasudil hydrochloride injection, diquinonium chloride tablets, caffeine citrate injection, levofloxacin injection, terbutaline sulfate injection, pentazocin injection, salbutamine sulfate injection, pentoxifylline injections, etc. Corporate honors: The company won the honorary title of “Civilized Enterprise”, “2018 Top Ten Enterprises” and “2018 Advanced Unit for Work Safety” in Rizhao High-tech Zone. It was awarded the 2018 Advanced Unit for Trade Union Work by the Laoshan District Federation of Trade Unions. The company won a series of honors such as “2018 China's Top 100 Chemical and Pharmaceutical Industry Enterprises Comprehensive Strength”, “2018 China's Chemical and Pharmaceutical Industry Integration Promotion Excellent Enterprise Brand”, “National Key Technological Transformation 'Double High and One Excellent” Project, “National AAA Credit Enterprise”, “Shandong Pharmaceutical Industry Outstanding Enterprise in the 60th Anniversary of the Founding of the Nation”, “Shandong Quality Management Award”, and “China's Top 100 Chemical and Pharmaceutical Industry Enterprises with Comprehensive Strength”.

Company Profile

Short Name-A华仁药业
Symbol-A300110
Listing DateAug 25, 2010
Issue Price13.99
Shares Offered53.60M share(s)
FoundedMay 20, 1998
Legal Representativexiaodong yang
General Managerjian li
Secretaryxiangyuan meng
Accounting FirmZTE Accounting firm (special general partnership)
Securities Representativewentao yan
Legal CounselBeijing Zhide (Shanghai) Law Firm
Employees588
Phone0532-58070788
Office AddressNo. 187, Zhuzhou Road, High-tech Industrial Park, Qingdao
Zip Code266101
Registered AddressNo. 187, Zhuzhou Road, High-tech Industrial Park, Qingdao, Shandong
Fax0532-58070286
Emailhuaren@qdhuaren.com
Business License370200018065427
BusinessLicensed items: pharmaceutical production; pharmaceutical wholesale; pharmaceutical retail; drug import and export; pharmaceutical contract production; Class II medical device production; Class III medical device production; Class III medical device management; hygiene products and disposable medical supplies production; cosmetics production; food production; food sales; road cargo transportation (excluding dangerous goods); urban distribution and transportation services (excluding dangerous goods). (Projects subject to approval by law can business activities be carried out only after approval by relevant departments; specific business projects are subject to the relevant department's approval documents or licenses) General projects: Class I medical device production; Class I medical device sales; Class II medical device sales; medical packaging materials manufacturing; packaging materials and products sales; packaging services; rubber products manufacturing; rubber products sales; plastic products sales; mold manufacturing; cosmetics wholesale; cosmetics retail; hygiene products and disposable medical products sales; daily mask (non-medical) production; daily mask (non-medical) production; daily mask (non-medical) production Medical) sales; sales of labor protection products; production of labor protection products; manufacturing of industrial textile products; sales of industrial textile products; import and export of goods; technology import and export; Internet sales (except for the sale of goods requiring permission); handling; manufacturing of non-ferrous metal alloys; processing of mechanical parts and components. (With the exception of projects subject to approval by law, independent business activities are carried out on the basis of a business license in accordance with the law)

Company Executives

  • Name
  • Position
  • Salary
  • xiaodong yang
  • Chairman, Directors, Chairman of the Strategy Committee, Nomination Committee Members
  • --
  • li zhang
  • Directors, Strategy Committee Member
  • --
  • subin zhu
  • Directors, Strategy Committee Member
  • --
  • chuanwen dong
  • Directors, Nomination Committee Members
  • --
  • yan dong
  • Directors, Strategy Committee Member
  • --
  • zhihua huang
  • Directors, Member of the Remuneration and Assessment Committee
  • --
  • genfu feng
  • Independent Directors, Audit Committee Member, Strategy Committee Member, Chairman of the Nomination Committee
  • 100.00K
  • yong liu
  • Independent Directors, Nomination Committee Members, Chairman of the Remuneration and Assessment Committee, Audit Committee Member
  • 100.00K
  • tianxi zhang
  • Independent Directors, Nomination Committee Members, Member of the Remuneration and Assessment Committee, Chairman of the Audit Committee
  • 100.00K
  • xiangyuan meng
  • Board Secretary, VP
  • --
  • wentao yan
  • Securities Affairs Representative
  • --
  • li qiang
  • Chairman of the Supervisory Board, Shareholder Supervisors
  • 100.00K
  • wei zhang
  • Auditors
  • --
  • jian li
  • President
  • 588.50K
  • xinguang feng
  • VP
  • 593.80K
  • ming li
  • VP
  • 659.90K
  • junhong wang
  • VP
  • 642.80K
  • liping han
  • VP, Chief Financial Officer
  • 880.90K
  • junwei song
  • Employee Supervisors
  • 253.90K
  • liang hong
  • Executive President
  • 970.60K